KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.

Mark M Awad, Patrick M Forde, Nicolas Girard, Jonathan Spicer, Changli Wang, Shun Lu, Tetsuya Mitsudomi, Enriqueta Felip, Stephen R Broderick, Scott J Swanson, Julie Brahmer, Keith Kerr, Gene B Saylors, Ke-Neng Chen, Vishwanath Gharpure, Jaclyn Neely, David Balli, Nan Hu, Mariano Provencio Pulla

J Clin Oncol 43(12) 1453-1462

PMID39778121
PMCIDPMC12005868
DOI10.1200/JCO-24-02239
发表日期2025-01-08
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: Neoadjuvant immune checkpoint blockade with nivolumab plus ipilimumab improves overall survival (OS) in non-small cell lung cancer (NSCLC); however, randomized data for resectable lung cancer are limited. We report results from the exploratory concurrently randomized nivolumab plus ipilimumab and chemotherapy arms of the international phase III CheckMate 816 trial. METHODS: Adults with stage IB-IIIA (American Joint Committee on Cancer seventh edition) resectable NSCLC received three cycles of nivolumab once every 2 weeks plus one cycle of ipilimumab or three cycles of chemotherapy (on day 1 or days 1 and 8 of each 3-week cycle) followed by surgery. Analyses included event-free survival (EFS), OS, pathologic response, surgical outcomes, biomarker analyses, and safety. RESULTS: A total of 221 patients were concurrently randomly assigned to nivolumab plus ipilimumab (n = 113) or chemotherapy (n = 108). At a median follow-up of 49.2 months, the median EFS was 54.8 months (95% CI, 24.4 to not reached [NR]) with nivolumab plus ipilimumab versus 20.9 months (95% CI, 14.2 to NR) with chemotherapy (HR, 0.77 [95% CI, 0.51 to 1.15]); 3-year EFS rates were 56% versus 44%. Higher rates of EFS events were initially seen, with later benefit favoring nivolumab plus ipilimumab; 3-year OS rates were 73% versus 61% (HR, 0.73 [95% CI, 0.47 to 1.14]); pathologic complete response rates were 20.4% versus 4.6%, respectively. In the respective arms, 83 (74%) and 82 patients (76%) underwent definitive surgery. Grade 3-4 treatment-related adverse events occurred in 14% and 36% of patients, respectively. CONCLUSION: Neoadjuvant nivolumab plus ipilimumab showed potential long-term clinical benefit versus chemotherapy, despite early crossing of EFS curves in the preoperative phase and a lower rate of high-grade toxicity.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

FIG 3.

Baseline four-gene inflammatory signature score by (A) pCR, (B) MPR, and (C) EFS in the nivolumab plus ipilimumab arm and (D) EFS in the chemotherapy arm. The four-gene inflammatory signature comprised CD8A , STAT1 , LAG3 , and CD274 (encoding PD-L1) 15 and was assessed by RNA sequencing of evaluable tumor samples at baseline; scores were grouped as high or low relative to the median z -score across the data set. pCR (0% RVT) and MPR (≤10% RVT) postsurgery in both primary tumor (lung) and sampled lymph nodes per BIPR. EFS was per BICR. Patients who received subsequent therapy were censored at the last evaluable tumor assessment on or before the date of subsequent therapy. BICR, blinded independent central review; BIPR, blinded independent pathologic review; EFS, event-free survival; HR, hazard ratio; MPR, major pathologic response; NR, not reached; pCR, pathologic complete response; RVT, residual viable tumor.

C

Event-Free Survival

FIG 3. · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

Event-Free Survival

FIG 3. · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.CONSORT diagram of patient disposition. a Includes patients randomly assigned to receive nivolumab plus chemotherapy (n = 179) and chemotherapy (n = 105; these patients were not concurrently randomly assigned to the nivolumab plus ipilimumab arm and are not included in this analysis) in the revised protocol. b One patient randomly assigned to the nivolumab plus ipilimumab arm incorrectly received chemotherapy (this patient is counted in the nivolumab plus ipilimumab arm for baseline and efficacy analyses and in the chemotherapy arm for exposure and safety analyses). c Includes grade 2 pneumonitis, grade 3 pulmonary thromboembolism, and grade 3 diarrhea (n = 1 each). d Includes refusal of surgery or withdrawal of consent (n = 4 per arm), unresectable tumor (n = 1 per arm), patient who was randomly assigned but never treated (n = 1 per arm), patient who was unfit for surgery (nivolumab plus ipilimumab, n = 2; chemotherapy, n = 5), and patient who achieved a complete response (chemotherapy, n = 1).
非 KM Figure
FIG 2.(A) EFS, (B) pCR, (C) MPR, and (D) EFS in patients with or without a pCR and (E) OS with nivolumab plus ipilimumab versus chemotherapy. EFS per BICR was determined among concurrently randomly assigned patients; patients who received subsequent therapy were censored at the last evaluable tumor assessment on or before the date of subsequent therapy. pCR (0% RVT) and MPR (≤10% RVT) postsurgery in both primary tumor (lung) and sampled lymph nodes per BIPR; patients who did not undergo surgery were classified as nonresponders. The OR was calculated using the stratified Cochran-Mantel-Haenszel method. a Not computed because of the low number of patients with a pCR (n = 5). BICR, blinded independent central review; BIPR, blinded independent pathologic review; EFS, event-free survival; HR, hazard ratio; MPR, major pathologic response; NR, not reached; OR, odds ratio; OS, overall survival; pCR, pathologic complete response; RVT, residual viable tumor.
非 KM Figure